Two pioneering works published when only an early-generation PI3K inhibitor (LY294002) was available suggested that LY294002 at a high molar concentration is required to erase AKT phosphorylation [42], and the cancer cell growth inhibition efficiency was suboptimal [43]. The gene discussed is PIK3CB; the disease is cancer.